Related Experiment Video

Updated: Jun 4, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

A common polymorphism of CYP4A11 is associated with blood pressure in a Chinese population

Rong Zhang1, Jingyi Lu, Cheng Hu

  • 1Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai Clinical Center of Diabetes, Shanghai, China.

Hypertension Research : Official Journal of the Japanese Society of Hypertension
|February 18, 2011
PubMed

Insights

Genetic variants in the cytochrome P450, family 4, gene A11 (CYP4A11) were studied in a Chinese population. A common CYP4A11 variant was linked to blood pressure in men, suggesting a role in hypertension risk.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Pharmacogenomics

Background:

  • Cytochrome P450, family 4, gene A11 (CYP4A11) variants are implicated in hypertension.
  • Limited data exists on CYP4A11's role in hypertension within Chinese populations.

Purpose of the Study:

  • To investigate the association between CYP4A11 gene variants and hypertension prevalence.
  • To evaluate the effect of CYP4A11 variants on blood pressure levels in a Chinese cohort.

Main Methods:

  • Genotyping of three single nucleotide polymorphisms (rs9332982, rs4660980, rs3890011) in 1734 participants.
  • Exclusion of individuals with secondary hypertension.
  • Sex-pooled and sex-specific analyses for genotype-phenotype associations.

Main Results:

  • The rs9332982 T allele showed a nominal association with increased hypertension prevalence in women (OR: 1.38, P=0.0183), which did not persist after Bonferroni correction.
  • The rs4660980 variant was significantly associated with lower systolic (β=-3.17, P=0.0011) and diastolic blood pressure (β=-1.75, P=0.0010) in normotensive men.

Conclusions:

  • A common CYP4A11 variant is associated with blood pressure regulation in the Chinese population.
  • Further research is warranted to validate these findings and elucidate the mechanisms involved in CYP4A11's effect on blood pressure.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...